NASDAQ:NTRB Nutriband Q4 2025 Earnings Results & Report $6.65 +0.60 (+9.92%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$6.73 +0.08 (+1.14%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nutriband missed analyst expectations on both earnings and revenue in its Q4 2025 results, released April 28, 2025. The company reported EPS of -$0.18 versus the -$0.12 consensus estimate, while revenue of $0.64 million fell short of the $0.71 million estimate by $0.07 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 28, 2025TimeBefore Market Opens Nutriband EPS ResultsActual EPS-$0.18Consensus EPS -$0.12Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersNutriband Revenue ResultsActual Revenue$0.64 millionExpected Revenue$0.71 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/AUpcoming EarningsNutriband's next earnings date is estimated for Monday, December 7, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Nutriband Q4 2025 Earnings FAQ Did Nutriband beat earnings estimates for Q4 2025? Nutriband (NASDAQ:NTRB) reported earnings of -$0.18 per share for Q4 2025, missing the consensus estimate of -$0.12. The report was announced on Monday, April 28, 2025. What was Nutriband's revenue for Q4 2025? Nutriband reported revenue of $0.64 million for Q4 2025, against a consensus estimate of $0.71 million. When is Nutriband's next earnings date? Nutriband's next earnings date is estimated for Monday, December 7, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nutriband on the company's earnings history page. Nutriband Earnings HeadlinesNutriband Seeks New Patent Protection For AVERSA Transdermal TechnologyOctober 8 at 7:58 PM | rttnews.comNutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent TechnologyOctober 8 at 7:00 AM | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Nutriband Inc.: Nutriband Marks Five Years on Nasdaq - CEO Letter to ShareholdersOctober 2, 2026 | finanznachrichten.deNutriband Marks Five Years on Nasdaq – CEO Letter to ShareholdersOctober 1, 2026 | globenewswire.comFinancial Review: Evolus (NASDAQ:EOLS) vs. Nutriband (NASDAQ:NTRB)September 30, 2026 | americanbankingnews.comSee More Nutriband Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email. Email Address About NutribandNutriband (NASDAQ:NTRB) (NASDAQ:NTRB) develops and manufactures transdermal patches and other wearable drug-delivery products for pharmaceutical, over-the-counter, consumer, and wellness markets. The company’s capabilities include product development, formulation, manufacturing, packaging, and private-label services for customers seeking patch-based delivery systems. Nutriband’s portfolio includes consumer and wellness patches, as well as prescription-focused transdermal technologies. Its AVERSA platform is designed to incorporate abuse-deterrent features into transdermal products, with the goal of helping reduce the risk of drug extraction, misuse, or abuse. The company has also pursued applications for controlled-substance delivery, including an abuse-deterrent fentanyl patch in development. The company serves customers in pharmaceutical, healthcare, and consumer-product markets and operates from the United States. Nutriband became publicly traded on the Nasdaq under the symbol NTRB in 2022. Its business combines contract and private-label manufacturing with the development of proprietary transdermal technologies and branded patch products.View Nutriband ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part Begins Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
